NCT01611090 2020-03-03
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
Clinical Trials
6 trialsNCT01466153 2017-05-31
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
MedImmune LLC
Phase 2 Completed
NCT01520922 2017-01-19
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Phase 2 Completed
NCT01871675 2016-07-11
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01649622 2012-11-08
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn